Drug news
Viibryd success in three Phase III studies for Generalised Anxiety Disorder- Forest Labs
Forest Laboratories, Inc.announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone ( known as Viibryd) in adult patients with Generalized Anxiety Disorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients who received vilazodone demonstrated statistically significant improvement from baseline in the Hamilton Rating Scale for Anxiety (HAM-A) total score versus placebo at week 8, the primary endpoint.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins